ERAS

Important Notice to Long-Term Shareholders of Erasca, Inc. (NASDAQ: ERAS); Insulet Corporation (NASDAQ: PODD); New Era Energy & Digital, Inc. (NASDAQ: NUAI) (formerly known as New Era Helium (NASDAQ: NEHC)); and Power Solutions International, Inc. (NASDAQ: PSIX): Grabar Law Office is Investigating Claims on Your Behalf

Erasca governance probe over ERAS-0015 disclosures could signal risk

<section class="insight" data-version="1">
  <section data-block="information">
    <h3>Information</h3>
    <p>&lt;link type=&quot;text/css&quot; rel=&quot;stylesheet&quot; href=&quot;https://www.globenewswire.com/styles/gnw_nitf.css&quot;&gt;&lt;/li...</p>
  </section>

  <section data-block="ai-summary-paragraph">
    <h3>AI Summary</h3>
    <p>Grabar Law Office is probing Erasca&#039;s officers for fiduciary duties related to ERAS-0015 disclosures. The investigation follows April 27, 2026 disclosures highlighting patent/trade-secret concerns and a patient death, which coincided with a stock decline. The outcome could drive governance reforms or civil actions, driving near-term ERAS volatility and potential valuation implications.</p>
  </section>

  <section data-block="ai-summary-bullets">
    <h3>Key Points</h3>
    <ul><li>Grabar Law Office investigating Erasca directors for fiduciary duties breaches.</li><li>Focus on ERAS-0015 disclosures and governance controls.</li><li>April 27, 2026 disclosures cited patent/trade-secret concerns and a death.</li><li>Shareholders may pursue reforms, damages, or court-approved incentives at no cost.</li><li>Other companies named include Insulet PODD, New Era Energy NUAI, and PSIX.</li></ul>
  </section>

  <section data-block="companies-mentioned">
    <h3>Companies Mentioned</h3>
    <ul><li><strong>Erasca, Inc. (ERAS)</strong>: Subject of governance probe related to ERAS-0015 statements; potential impact on governance and valuation.</li><li><strong>Insulet Corporation (PODD)</strong>: Mentioned in the release; not directly ERAS but signals broader litigation risk in healthcare/naval sectors; potential spillover sentiment effect.</li><li><strong>New Era Energy &amp; Digital, Inc. (NUAI)</strong>: Allegations of fiduciary breaches; governance risk could affect investors in growth-focused data-center ventures.</li><li><strong>Power Solutions International, Inc. (PSIX)</strong>: Similar shareholder investigations; could weigh sentiment on industrial/tech infrastructure names.</li></ul>
  </section>

  <section data-block="category">
    <h3>Legal</h3>
    <p>Category: Legal. Fits as a shareholder governance and securities-law investigation with potential market implications for ERAS and peers.</p>
  </section>

  <section data-block="market-moving">
    <h3>Market-Moving</h3>
    <ul><li>Potential governance-related developments could cause near-term ERAS price swings.</li><li>April 2026 disclosures linked to ERAS-0015 issues have pressured sentiment.</li><li>Lawsuit dynamics may influence investor perception of ERAS risk exposure.</li><li>Spillover risk if other named firms face similar probes.</li></ul>
  </section>

  <section data-block="key-facts">
    <h3>Key Facts</h3>
    <ul><li>Date of public investigation note: July 29, 2026.</li><li>ERAS-0015 is a pan-RAS molecular glue candidate for RAS-mutant solid tumors.</li><li>April 27, 2026 disclosures included patent/trade-secret concerns and a death.</li><li>ERAS share price declined following the April disclosures.</li><li>Shareholders holding since before Jan 14, 2025 may pursue reforms and damages.</li></ul>
  </section>

  <section data-block="trading-thesis">
    <h3>Trading Thesis</h3>
    <p>Near-term ERAS volatility persists; upside hinges on governance outcomes and settlement clarity.</p>
  </section>
</section>


<article>
  <section>
    <p>PHILADELPHIA, July 29, 2026 (GLOBE NEWSWIRE) — <strong>ERAS</strong>CA, INC. (NASDAQ: <strong>ERAS</strong>) and Insulet Corporation (NASDAQ: <strong>PODD</strong>) are the subjects of new inquiries led by Grabar Law Office. The investigations assess potential breaches of fiduciary duties by certain officers and directors of both companies. This report summarizes the allegations, disclosures, and actions available to eligible shareholders.</p>
  </section>

  <section>
    <h2>Erasca, Inc. Investigation Details</h2>

    <section>
      <h3>What Is This Investigation About?</h3>
      <p><strong>The investigation concerns</strong> whether Erasca's directors and senior executives maintained appropriate oversight, disclosure controls, compliance procedures, and risk-management systems relating to the Company&#39;s public statements concerning ERAS-0015, a pan-RAS molecular glue candidate being developed for the treatment of RAS-mutant solid tumors.</p>
    </section>

    <section>
      <h3>Shareholder Eligibility and How to Seek Relief</h3>
      <p><strong>If you are a current Erasca (NASDAQ:<a class="ticker" href="https://www.benzinga.com/quote/ERAS">ERAS</a>) shareholder who has held shares since prior to January 14, 2025, you seek corporate governance reforms, damages on behalf of the Company, and a court approved incentive award at no cost to you whatsoever. Please visit </strong><a href="https://www.globenewswire.com/Tracker?data=xAdx9ra4LPml9JKxA5iNo4SM_fg_rCxUUnckssQGmBykc1mpF9PuuivULbxtyiN0r4gZV-9keTAPrPWgpd9vzFaSswrw0CQJZslAhgNDr_eutiSExva5gE-39LzBezxCuVuOa_tXlH8UnKiCSmlyd1eaOibrsGjHfuUNS4Xz-XhA2glCXa4fbnt9X_0UGVwwhwkmgaM6hcML9cToqoQ-XA==" rel="nofollow" target="_blank"><strong>https://grabarlaw.com/the-latest/erasca-shareholder-investigation/</strong></a><strong>, </strong><strong>contact Joshua H. Grabar at </strong><a href="https://www.globenewswire.com/Tracker?data=T-uJnlgWCGGM5-mQ5--RTPSFSJIReHPhBVvgmrl3kHCVVOk51sXi48NTYKgpcqmnxCw-IRJw_mLuJp6JOcgPkfO2_TBOQGZunKMVtc3yhgo=" rel="nofollow" target="_blank"><strong>jgrabar@grabarlaw.com</strong></a><strong>, or call us at 267-507-6085.</strong></p>
    </section>

    <section>
      <h3>What Is Alleged?</h3>
      <p>According to a recently filed federal securities class action Erasca, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/quote/ERAS">ERAS</a>), through certain of its officers, made materially misleading statements and omissions concerning ERAS-0015. Among other things, the underlying class action complaint alleges that: Erasca publicly promoted ERAS-0015 as a potential &#34;best-in-class&#34; therapy and made repeated comparisons between ERAS-0015 and Revolution Medicines&#39; RMC-6236; the Company&#39;s public disclosures allegedly relied upon improper comparisons to RMC-6236; Erasca allegedly faced intellectual property, patent, and trade-secret-related risks associated with those comparisons and related disclosures; investors allegedly were not adequately informed of those risks; and certain positive statements regarding ERAS-0015 allegedly lacked a reasonable basis when made.</p>
    </section>

    <section>
      <h3>April 2026 Disclosures</h3>
      <p><strong>April 2026 Disclosures:</strong> On April 27, 2026, Erasca disclosed that it had received correspondence from counsel for Revolution Medicines alleging, among other things, patent infringement, trade-secret-related issues, and allegedly improper comparative statements concerning ERAS-0015 and RMC-6236. Later that same day, Erasca disclosed preliminary Phase 1 clinical data regarding ERAS-0015 and reported that one patient who received ERAS-0015 had died after experiencing pneumonitis that progressed following withdrawal of supportive care. The Company also disclosed that comparisons between ERAS-0015 and other product candidates were based on cross-study analyses rather than head-to-head clinical trials and that such comparisons were inherently limited. Following these disclosures, Erasca&#39;s share price experienced a substantial decline.</p>
    </section>

    <section>
      <h3>What Can You Do Now?</h3>
      <p><strong>What Can You Do Now?</strong><strong> If you are a current Erasca, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/quote/ERAS">ERAS</a>) shareholder and have held shares since prior to January 14, 2025, you can seek corporate governance reforms, damages on behalf of the Company, and a court approved incentive award at no cost to you whatsoever. Please visit </strong><a href="https://www.globenewswire.com/Tracker?data=xAdx9ra4LPml9JKxA5iNo4SM_fg_rCxUUnckssQGmBykc1mpF9PuuivULbxtyiN0r4gZV-9keTAPrPWgpd9vzE8tpc22q8cVMrhefVeZ2CwUfcVBM6hSJP1TnR3t9j54knDPO4kTRMyUqAf9NOEyiEwKkz-CjPNJG9gqjaQciVq7xPuwbm9xNuGJg4fGbl1kWqHIA51f9jgPAJp0SPRnFQ==" rel="nofollow" target="_blank"><strong>https://grabarlaw.com/the-latest/erasca-shareholder-investigation/</strong></a><strong>, </strong><strong>contact Joshua H. Grabar at </strong><a href="https://www.globenewswire.com/Tracker?data=T-uJnlgWCGGM5-mQ5--RTPSFSJIReHPhBVvgmrl3kHC3Y5pHYh6uoFUHpbQrMZvlfBSBRRJ0mg7DcnLLCYXOfm5dTiCiDjUJgYlaQU0PFA4=" rel="nofollow" target="_blank"><strong>jgrabar@grabarlaw.com</strong></a><strong>, or call us at 267-507-6085.</strong></p>
    </section>
  </section>

  <section>
    <h2>Insulet Corporation Investigation</h2>

    <section>
      <h3>Overview</h3>
      <p><strong>INSULET CORPORATION (NASDAQ:<a class="ticker" href="https://www.benzinga.com/quote/PODD">PODD</a>):</strong> Grabar Law Office is investigating claims on behalf of shareholders of <strong>Insulet Corporation</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/quote/PODD">PODD</a>).</p>
    </section>

    <section>
      <h3>What Is This Investigation About?</h3>
      <p><strong>The investigation concerns</strong> whether certain officers and directors breached the fiduciary duties they owed to the company.</p>
    </section>

    <section>
      <h3>Shareholder Eligibility and How to Seek Relief</h3>
      <p><strong>If you purchased</strong> <strong>Insulet Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/quote/PODD">PODD</a>)</strong> <strong>shares prior to February 21, 2025</strong><strong>, </strong><strong>and still hold shares today, </strong><strong>you can seek corporate reforms, the return of funds back to the company, and a court approved incentive award at no cost to you whatsoever.</strong> <strong>Please visit </strong><a href="https://www.globenewswire.com/Tracker?data=xAdx9ra4LPml9JKxA5iNo4SM_fg_rCxUUnckssQGmBwyGnPcFO2QDd-ccwaV1y4lRH9CbluydStNWmJjwu0AXaX6nFFY217caZgIAszeHuNdhkex1H5XHbFatlI19GlrnQRjR-b6s34TSJDagncx9Iqq8PUDcHKiR_hKrcItLQWVBdjltAE-_ywL8VXJtJwnPflXcVlm73iIU7_OxWJKM-s_7KnxhsGC-2MLxflhBeY=" rel="nofollow" target="_blank"><strong>https://grabarlaw.com/the-latest/insulet-shareholder-investigation/</strong></a><strong>, </strong><strong>contact Joshua Grabar at </strong><a href="https://www.globenewswire.com/Tracker?data=T-uJnlgWCGGM5-mQ5--RTPSFSJIReHPhBVvgmrl3kHCYmSfat7bjjvovXtYgctz77xwx1Cq2LwiTqttp-jZNGhCp1iNvngKjhS1sXHakQGY=" rel="nofollow" target="_blank"><strong>jgrabar@grabarlaw.com</strong></a><strong>, </strong><strong>or call 267-507-6085. </strong></p>
    </section>

    <section>
      <h3>What Is Alleged?</h3>
      <p><strong>As alleged in a recently filed federal securities fraud class action</strong>, Insulet Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/quote/PODD">PODD</a>), through certain of its executives, violated federal securities laws by making false and/or misleading statements and/or failed to disclose that: (i) Insulet’s manufacturing controls and procedures were defective; (ii) the foregoing created a foreseeable heightened risk that one or more Insulet products would be found to be in violation of applicable safety regulations and/or pose a risk of injury; and (iii) as a result, Defendants’ public statements were materially false and misleading at all relevant times.</p>
    </section>

    <section>
      <h3>Disclosures and Developments</h3>
      <p><strong>The truth began to emerge on March 12, 2026</strong>, when Insulet disclosed that it had "initiated a voluntary Medical Device Correction for specific lots of Omnipod&#xAE; 5 Pods after identifying a manufacturing issue through its ongoing product monitoring." Then, <strong>on May 26, 2026</strong>, Insulet disclosed the "initat[ion]" of another "voluntary Me...</p>
    </section>
  </section>
</article>

Grabar Law Office is probing Erasca's officers for fiduciary duties related to ERAS-0015 disclosures. The investigation follows April 27, 2026 disclosures highlighting patent/trade-secret concerns and a patient death, which coincided with a stock decline. The outcome could drive governance reforms or civil actions, driving near-term ERAS volatility and potential valuation implications.

important-notice-to-long-term-shareholders-of-erasca-inc-nasdaq-eras-insulet-corporation-nasdaq-podd-new-era-energy-digital-inc-nasdaq-nuai-formerly-known-as-new-era-helium-nasdaq-nehc-and-power-solutions-international-inc-nasdaq-psix-grabar-law-office-is-investigating-claims-on-your-behalf

News insight

AI summary

Sentiment rationale

Key facts

Legal